Aug 6 |
IDEAYA Biosciences, Inc. Reports Second Quarter 2024 Financial Results and Provides Business Update
|
Aug 1 |
IDEAYA Biosciences, Inc. (IDYA) Expected to Beat Earnings Estimates: Should You Buy?
|
Jul 31 |
IDEAYA in license agreement with Biocytogen for antibody drug conjugate program
|
Jul 31 |
Biocytogen Announces Option and License Agreement with IDEAYA Biosciences for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program
|
Jul 31 |
IDEAYA Biosciences Announces Option and License Agreement for Potential First-in-Class B7H3/PTK7 Topo-I-Payload Bispecific ADC Program with Biocytogen
|
Jul 29 |
IDEAYA Biosciences to Participate in Upcoming August 2024 Investor Relations Event
|
Jul 23 |
How Much Upside is Left in IDEAYA Biosciences (IDYA)? Wall Street Analysts Think 32.97%
|
Jul 15 |
Industry Analysts Just Made A Meaningful Upgrade To Their IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Revenue Forecasts
|
Jul 11 |
IDEAYA Announces Closing of Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares
|
Jul 11 |
Biotech Stock Roundup: KYMR, IDYA, QURE Soar on Study Data, HLVX Tanks on Study Failure
|